Cost and value: Everything or nothing?

Public Health

Volumn 120, Issue 4, 2006, Pages 281-282

  Mackie, Phil ^a   Sim, Fiona ^a  

^a The Royal Society for Public Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

PUBLIC HEALTH;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; ECONOMIC EVALUATION; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; NATIONAL HEALTH SERVICE; NEW ZEALAND; PUBLIC HEALTH SERVICE; PUBLISHING; SKILL; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED KINGDOM;

DECISION MAKING; HEALTH POLICY; HUMANS; MODELS, ECONOMETRIC; PUBLIC HEALTH PRACTICE;

EID: 33644873100     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.puhe.2006.02.001     Document Type: Editorial

References (5)

1. BBC News Online. Alzheimer's drugs policy reviewed. (Available at: http://news.bbc.co.uk/1/hi/health/4637484.stm. Last accessed 25th January 2006).
2. G. Rose Sick individuals and sick populations Int J Epidemiol 14 1985 32-38
3. J.F. Blumstein The Oregon experiment: The role of cost-benefit analysis in the allocation of Medicaid funds Soc Sci Med 45 1997 545-554
4. Gauld R, Bloomfield A, Kiro C, Lavis J, Ross S. Conceptions and uses of public health ideas by New Zealand government policymakers: Report on a five-agency survey. Public Health, this issue, doi: 10.1016/ j.puhe.2005.10.008.
5. Wikiquote. Oscar Wilde. (Available at: http://en.wikiquote.org/wiki/Oscar_Wilde. Last accessed 26th January 2006).